Of note, CSC-enriched fractions prepared from prostate cancer tissues highly expressed RUNX2 as well as its target gene Survivin, implying that RUNX2 might be associated with the biology of CSC in prostate cancer [47,48]. The gene discussed is RUNX2; the disease is prostate carcinoma.